SG11202010159RA - Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof - Google Patents

Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof

Info

Publication number
SG11202010159RA
SG11202010159RA SG11202010159RA SG11202010159RA SG11202010159RA SG 11202010159R A SG11202010159R A SG 11202010159RA SG 11202010159R A SG11202010159R A SG 11202010159RA SG 11202010159R A SG11202010159R A SG 11202010159RA SG 11202010159R A SG11202010159R A SG 11202010159RA
Authority
SG
Singapore
Prior art keywords
heterodimeric
fusion proteins
fusion
proteins
Prior art date
Application number
SG11202010159RA
Inventor
Matthew Bernett
John Desjarlais
Rumana Rashid
Rajat Varma
Christine Bonzon
Original Assignee
Xencor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xencor Inc filed Critical Xencor Inc
Publication of SG11202010159RA publication Critical patent/SG11202010159RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202010159RA 2018-04-18 2019-04-18 Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof SG11202010159RA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862659563P 2018-04-18 2018-04-18
US201862684143P 2018-06-12 2018-06-12
US201862724396P 2018-08-29 2018-08-29
US201862756800P 2018-11-07 2018-11-07
PCT/US2019/028107 WO2019204592A1 (en) 2018-04-18 2019-04-18 Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof

Publications (1)

Publication Number Publication Date
SG11202010159RA true SG11202010159RA (en) 2020-11-27

Family

ID=68239907

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202010159RA SG11202010159RA (en) 2018-04-18 2019-04-18 Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof

Country Status (13)

Country Link
US (2) US20190365861A1 (en)
EP (1) EP3781596A1 (en)
JP (1) JP2021522175A (en)
KR (1) KR20210003170A (en)
CN (1) CN112105645A (en)
AU (1) AU2019255744A1 (en)
CA (1) CA3097625A1 (en)
IL (2) IL310398A (en)
MA (1) MA52289A (en)
MX (1) MX2020010912A (en)
SG (1) SG11202010159RA (en)
TW (1) TW202011984A (en)
WO (1) WO2019204592A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201903302UA (en) 2016-10-14 2019-05-30 Xencor Inc Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
MX2019006072A (en) * 2016-11-30 2019-08-14 Oncomed Pharm Inc Methods for treatment of cancer comprising tigit-binding agents.
US11524991B2 (en) 2018-04-18 2022-12-13 Xencor, Inc. PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
CN112437777A (en) 2018-04-18 2021-03-02 Xencor股份有限公司 TIM-3 targeting heterodimeric fusion proteins comprising an IL-15/IL-15RA Fc fusion protein and a TIM-3 antigen binding domain
JP2022504550A (en) 2018-10-12 2022-01-13 ゼンコア インコーポレイテッド Use in PD-1 targeted IL-15 / IL-15R alpha FC fusion proteins and their combination therapies
EP3897853A1 (en) 2018-12-20 2021-10-27 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
TW202128757A (en) 2019-10-11 2021-08-01 美商建南德克公司 Pd-1 targeted il-15/il-15ralpha fc fusion proteins with improved properties
WO2021092719A1 (en) * 2019-11-11 2021-05-20 王盛典 Fusion protein that targets antigen-specific t cells to induce differentiation thereof into memory stem cells
JP2023502712A (en) * 2019-11-21 2023-01-25 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） Novel PD-1-targeted immunotherapy with anti-PD-1/IL-15 immunocytokines
CA3164337A1 (en) * 2019-12-13 2021-06-17 Cugene Inc. Novel interleukin-15 (il-15) fusion proteins and uses thereof
CA3164353A1 (en) * 2019-12-13 2021-06-17 Cugene Inc. Cytokine-based bioactivatable drugs and methods of uses thereof
WO2021142476A1 (en) * 2020-01-12 2021-07-15 Dragonfly Therapeutics, Inc. Single-chain polypeptides
CN115397456A (en) * 2020-01-28 2022-11-25 基因泰克公司 IL15/IL15R alpha heterodimer Fc fusion proteins for the treatment of cancer
WO2021253360A1 (en) * 2020-06-18 2021-12-23 Proviva Therapeutics (Hong Kong) Limited Activatable procytokines
CN113321736B (en) * 2020-12-30 2024-01-09 苏州复融生物技术有限公司 Long-acting interleukin 15 fusion protein and preparation method and application thereof
WO2022170063A1 (en) * 2021-02-05 2022-08-11 Salubris Biotherapeutics, Inc. Il-15 fusion proteins and methods of making and using same
BR112023027312A2 (en) * 2021-06-23 2024-03-12 Cytune Pharma IMMUNOCYTOCIN
IL310372A (en) * 2021-07-28 2024-03-01 Genentech Inc Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of blood cancers
WO2023015198A1 (en) * 2021-08-04 2023-02-09 Genentech, Inc. Il15/il15r alpha heterodimeric fc-fusion proteins for the expansion of nk cells in the treatment of solid tumours
WO2023160721A1 (en) * 2022-02-28 2023-08-31 Wuxi Biologics (Shanghai) Co., Ltd. Heterodimeric polypeptide complexes comprising il-15 variants and uses thereof
KR20230171885A (en) * 2022-06-10 2023-12-21 메디맵바이오 주식회사 Fusion protein comprising anti-TIGIT antibody, interleukin-15, and interleukin-15 receptor alpha sushi domain, and uses thereof
WO2024011179A1 (en) * 2022-07-07 2024-01-11 Genentech, Inc. Combinations of il15/il15r alpha heterodimeric fc-fusion proteins and fcrh5xcd3 bispecific antibodies for the treatment of blood cancers
CN115806627A (en) * 2022-08-03 2023-03-17 深圳市先康达生命科学有限公司 Autocrine IL-15 and anti-LAG3 combined fusion protein and application thereof
CN116554356B (en) * 2023-05-16 2024-01-23 武汉大学 Fusion protein of hyper IL-15, sCD4 and Fc and application thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
EP0915987A2 (en) 1997-04-21 1999-05-19 Donlar Corporation POLY-($g(a)-L-ASPARTIC ACID), POLY-($g(a)-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE
CA2352783C (en) 1998-12-03 2012-04-10 The Regents Of The University Of California Stimulation of t cells against self antigens using ctla-4 blocking agents
KR100856446B1 (en) 1998-12-23 2008-09-04 화이자 인크. Human monoclonal antibodies to ctla-4
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US7449443B2 (en) 2000-03-23 2008-11-11 California Institute Of Technology Method for stabilization of proteins using non-natural amino acids
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
WO2003073238A2 (en) 2002-02-27 2003-09-04 California Institute Of Technology Computational method for designing enzymes for incorporation of amino acid analogs into proteins
AU2003288675B2 (en) 2002-12-23 2010-07-22 Medimmune Limited Antibodies against PD-1 and uses therefor
US7230068B2 (en) 2003-10-09 2007-06-12 Ambrx, Inc. Polymer derivatives
WO2005074650A2 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
JP5744369B2 (en) * 2004-02-27 2015-07-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Specific IL-15 mutant with IL-15 binding site and agonist / antagonist activity for IL15-Rα
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
CN109485727A (en) 2005-05-09 2019-03-19 小野药品工业株式会社 The human monoclonal antibodies of programmed death-1 (PD-1) and the method for carrying out treating cancer using anti-PD-1 antibody
MX2007015942A (en) 2005-07-01 2008-03-07 Medarex Inc Human monoclonal antibodies to programmed death ligand 1 (pd-l1).
US9244059B2 (en) 2007-04-30 2016-01-26 Immutep Parc Club Orsay Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
DK2170959T3 (en) 2007-06-18 2014-01-13 Merck Sharp & Dohme ANTIBODIES AGAINST HUMAN PROGRAMMED DEATH RECEPTOR PD-1
ES2639857T3 (en) 2008-02-11 2017-10-30 Cure Tech Ltd. Monoclonal antibodies for tumor treatment
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
AU2009288289B2 (en) 2008-08-25 2012-11-08 Amplimmune, Inc. PD-1 antagonists and methods of use thereof
CA2734908A1 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
TWI686405B (en) 2008-12-09 2020-03-01 建南德克公司 Anti-pd-l1 antibodies and their use to enhance t-cell function
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc Simultaneous inhibition of pd-l1/pd-l2
RS60033B1 (en) 2009-11-24 2020-04-30 Medimmune Ltd Targeted binding agents against b7-h1
PL2581113T3 (en) 2010-06-11 2018-11-30 Kyowa Hakko Kirin Co., Ltd. Anti-tim-3 antibody
CN103429620B (en) 2010-11-05 2018-03-06 酵活有限公司 There is the antibody design of the stable heterodimeric of mutation in Fc domains
BR112014012819B1 (en) 2011-11-28 2022-08-16 Merck Patent Gmbh ANTI-PD-L1 ANTIBODY OR ANTIGEN BINDING FRAGMENT AND COMPOSITION
UY34887A (en) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
EP3620473A1 (en) 2013-01-14 2020-03-11 Xencor, Inc. Novel heterodimeric proteins
KR102561553B1 (en) 2013-03-15 2023-07-31 젠코어 인코포레이티드 Heterodimeric proteins
JP6329343B2 (en) 2013-06-13 2018-05-23 任天堂株式会社 Image processing system, image processing apparatus, image processing program, and image processing method
HRP20212023T1 (en) * 2013-08-08 2022-04-01 Cytune Pharma Il-15 and il-15raplha sushi domain based modulokines
WO2015103928A1 (en) * 2014-01-08 2015-07-16 上海恒瑞医药有限公司 Il-15 heterogeneous dimer protein and uses thereof
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
JOP20200096A1 (en) 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof
TWI777174B (en) 2014-03-14 2022-09-11 瑞士商諾華公司 Antibody molecules to lag-3 and uses thereof
UA119167C2 (en) 2014-03-28 2019-05-10 Зенкор, Інк. Bispecific antibodies that bind to cd38 and cd3
KR20230028807A (en) * 2014-06-30 2023-03-02 알토 바이오사이언스 코포레이션 Il-15-based molecules and methods of use thereof
EP3169363A4 (en) 2014-07-16 2018-02-21 F. Hoffmann-La Roche AG Methods of treating cancer using tigit inhibitors and anti-cancer agents
CN114920840A (en) 2014-10-14 2022-08-19 诺华股份有限公司 Antibody molecules against PD-L1 and uses thereof
WO2016073789A2 (en) 2014-11-05 2016-05-12 Genentech, Inc. Anti-fgfr2/3 antibodies and methods using same
US10259887B2 (en) * 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
UY36471A (en) 2014-12-23 2016-06-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware ANTIBODIES AGAINST THE IMMUNORRECEPTOR (TIGIT) OF T LYMPHOCYTES WITH IG DOMAINS AND REASONS FOR INHIBITION OF THE TYMOSINE-BASED IMMUNORRECEPTOR (ITIM)
WO2016182751A1 (en) * 2015-05-08 2016-11-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and tumor antigens
TWI715587B (en) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Tigit-binding agents and uses thereof
JP6764474B2 (en) 2015-09-25 2020-09-30 ジェネンテック， インコーポレイテッド Anti-TIGIT antibody and usage
MA45255A (en) * 2016-06-14 2019-04-17 Xencor Inc BISPECIFIC CONTROL POINT INHIBITORS ANTIBODIES
SG11201903302UA (en) * 2016-10-14 2019-05-30 Xencor Inc Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments

Also Published As

Publication number Publication date
TW202011984A (en) 2020-04-01
MX2020010912A (en) 2021-01-29
IL310398A (en) 2024-03-01
WO2019204592A9 (en) 2019-12-12
WO2019204592A1 (en) 2019-10-24
CN112105645A (en) 2020-12-18
EP3781596A1 (en) 2021-02-24
MA52289A (en) 2021-02-24
IL278090B1 (en) 2024-03-01
US20190365861A1 (en) 2019-12-05
IL278090A (en) 2020-11-30
KR20210003170A (en) 2021-01-11
JP2021522175A (en) 2021-08-30
AU2019255744A1 (en) 2020-11-26
US20220040264A1 (en) 2022-02-10
AU2019255744A8 (en) 2021-04-22
CA3097625A1 (en) 2019-10-24
WO2019204592A8 (en) 2020-11-05

Similar Documents

Publication Publication Date Title
SG11202010159RA (en) Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
IL271704A (en) Targeted heterodimeric fc fusion proteins containing il-15/il-15rα and antigen binding domains
IL278091A (en) Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15rα fc-fusion proteins and pd-1 antigen binding domains and uses thereof
EP3806889A4 (en) Cytokine fusion proteins and uses thereof
IL275426A (en) Engineered il-2 fc fusion proteins
IL279510A (en) Progranulin-fc polypeptide fusion proteins and uses thereof
PH12019500782A1 (en) Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
EP3733716A4 (en) Fusion protein dimer using antibody fc region as backbone and use thereof
IL282223A (en) Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
IL277288A (en) Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
KR102201086B9 (en) Il-2 cd80 fusion protein comprising il-2 protein and cd80 protein and use thereof
IL278089A (en) Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15rα fc-fusion proteins and tim-3 antigen binding domains
IL275742A (en) Il-22 fc fusion proteins and methods of use
MA53822A (en) IL-12 HETERODIMER FC FUSION PROTEINS
EP3743438A4 (en) Cytokine fusion proteins
EP4072588A4 (en) Novel interleukin-15 (il-15) fusion proteins and uses thereof
EP3810171A4 (en) Novel interleukin-15 (1l-15) fusion proteins and uses thereof
IL278088A (en) Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15rα fc-fusion proteins and lag-3 antigen binding domains
EP3810172A4 (en) Heterodimeric proteins and uses thereof
IL278102A (en) Fusion proteins containing cd47 antibodies and cytokines
IL284679A (en) Multi-functional fusion proteins and uses thereof
IL276616A (en) Dosing for treatment with il-22 fc fusion proteins
SG11202110400QA (en) Fusion protein and use thereof
GB202201003D0 (en) Fusion polypeptide and use thereof
IL279057A (en) Endolysin-containing antimicrobial fusion proteins and uses thereof